Meeting
2022 ASCO Genitourinary Cancers Symposium
Biomarkers of gut microbial transfer and their association with cognitive impairment in long-term survivors of testicular germ cell tumors.
Authors
Michal Chovanec
Department of Oncology, Comenius University and National Cancer Institute, Bratislava, Slovakia
Michal Chovanec , Katarina Kalavska , Jana Obertova , Patrik Palacka , Katarina Rejlekova , Zuzana Sycova-Mila , Valentina De Angelis , Zuzana Orszaghova , Peter Lesko , Daniela Svetlovska , Beata Mladosievicova , Jozef Mardiak , Michal Pastorek , Barbora Vlkova , Peter Celec , Michal Mego
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 426)
DOI
10.1200/JCO.2022.40.6_suppl.426
Abstract #
426
Poster Bd #
K10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Longitudinal assessment of cognitive functioning in testicular germ cell tumor survivors.
First Author: Zuzana Orszaghova
Poster
2023 ASCO Genitourinary Cancers Symposium
Peripheral blood immune cell profiling in survivors of testicular germ cell tumors.
First Author: Michal Chovanec
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase II trial evaluating the efficacy of cabozantinib in the treatment of patients with refractory germ-cell tumors (GCT).
First Author: Jennifer King